Author

Ana P. Lacerda 1

1 AbbVie,North Chicago,United St

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, James D Lewis, Julian Panés, Edward V. Loftus, Jr, Geert R. D'Haens, ZHUQING YU, Bidan Huang, Ana P. Lacerda, Aileen L Pangan, Brian G. Feagan

COMPOSITE AND INDIVIDUAL MEASURES OF EFFICACY AND SAFETY AFTER 2 YEARS OF UPADACITINIB TREATMENT FOR CROHN'S DISEASE: RESULTS FROM THE ONGOING PHASE 2 CELEST OPEN-LABEL EXTENSION STUDY

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, John Liu, Ana P. Lacerda, Edward Loftus

CORRELATION BETWEEN CLINICAL AND ENDOSCOPIC ENDPOINTS AND REMISSION PER INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE IN PATIENTS WITH CROHN'S DISEASE: DATA FROM CELEST

Remo Panaccione, Stefan Schreiber, Gert Van Assche, Walter Reinisch, Edouard Louis, Timothy Zisman, Bruce Yacyshyn, Subrata Ghosh, Shariar Sedghi, Sasikiran Goteti, Wan-Ju Lee, Ana P. Lacerda

Efficacy and safety of upadacitinib as an induction therapy for patients with moderately-to-severely active ulcerative colitis: combined results from 382 subjects in the phase 2b study U-ACHIEVE

Peter D.R. Higgins, Xavier Hebuterne, Jesse Siffledeen, Wen Zhou, Fabio Cataldi, Wangang Xie, Ana P. Lacerda, Silvio Danese

EXPOSURE-RESPONSE RELATIONSHIPS FOR THE EFFECT OF UPADACITINIB ON CLINICAL AND ENDOSCOPIC EFFICACY ENDPOINTS IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE – ANALYSIS OF CELEST STUDY

Mohamed-Eslam F. Mohamed, Ben Klünder, Ana P. Lacerda, Ahmed A. Othman

Identification of biomarkers and mechanistic insight for upadacitinib in Crohn's disease: Serum inflammatory mediator analysis from the Phase 2b CELEST study

Severine Vermeire, Heath M. Guay, Bram Verstockt, Feng Hong, Wan-Ju Lee, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

IMPROVED PATIENT-REPORTED OUTCOMES WITH UPADACITINIB AS AN INDUCTION THERAPY FOR PATIENTS WITH ULCERATIVE COLITIS: DATA FROM U-ACHIEVE

Subrata Ghosh, Jean-Frederic Colombel, Severine Vermeire, Scott D. Lee, Wan-Ju Lee, Wen Zhou, Fabio Cataldi, Ana P. Lacerda, Silvio Danese

IMPROVEMENT IN PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: 52-WEEK DATA FROM THE CELEST STUDY

Laurent Peyrin-Biroulet, Edouard Louis, Edward Loftus Jr, Wan-Ju Lee, Fabio Cataldi, Ana P. Lacerda, Subrata Ghosh

Long-term efficacy and safety of upadacitinib treatment in patients with Crohn´s disease: One-year results of the ongoing phase 2 CELEST open-label extension study

Geert R. D'Haens, Julian Panés, Edouard Louis, Qian Zhou, David Pugatch, John Liu, Ana P. Lacerda, Edward Loftus

PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: PHASE 2 RESULTS FROM CELEST STUDY

Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus Jr, Namita Tundia, Mahesh Fuldeore, Ana P. Lacerda, Jeffrey Enejosa, Aileen L Pangan

Item 1 - 10 / 11
1
2